SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pluristem Therapeutics
PSTI 8.720+0.2%Aug 14 4:00 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: ACAN6/12/2018 8:03:15 AM
1 Recommendation

Recommended By
Savant

   of 295
 
PSTI reports positive top line results.

PLX-PAD treatment reduced risk of revascularization and improved patients’ mobility.
Study validates the design of Pluristem’s ongoing Pivotal Phase III study in Critical Limb Ischemia (CLI)

HAIFA, Israel, June 12, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( PSTI) ( PSTI.TA), a leading developer of placenta-based cell therapy products, today announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication (IC). PLX-PAD treatment reduced Incidence of revascularization and improved patients’ mobility. Study results also validate the design of Pluristem’s ongoing Pivotal Phase III study in CLI, a more severe stage of peripheral arterial disease (PAD) and confirm Pluristem’s proprietary Bio-Therapeutic approach.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News